Antimalarial Pharmacology and Therapeutics of Atovaquone 1 2

[1]  N. White,et al.  The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum , 2012, Malaria Journal.

[2]  D. Kyle,et al.  Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. , 2012, Journal of medicinal chemistry.

[3]  J. Hemingway,et al.  Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria , 2012, Proceedings of the National Academy of Sciences.

[4]  Sowmya R. Rao,et al.  Global TravEpiNet: a national consortium of clinics providing care to international travelers--analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  H. Ranson,et al.  Cytochrome b Mutation Y268S Conferring Atovaquone Resistance Phenotype in Malaria Parasite Results in Reduced Parasite bc1 Catalytic Turnover and Protein Expression , 2012, The Journal of Biological Chemistry.

[6]  D. Kyle,et al.  Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones. , 2011, Journal of medicinal chemistry.

[7]  F. Wit,et al.  Lower atovaquone and proguanil concentrations in patients taking efavirenz, lopinavir + ritonavir or atazanavir + ritonavir , 2011 .

[8]  P. Narciso,et al.  Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis , 2011, Malaria Journal.

[9]  A. Thomas,et al.  Towards an In Vitro Model of Plasmodium Hypnozoites Suitable for Drug Discovery , 2011, PloS one.

[10]  D. Koop,et al.  Optimization of endochin-like quinolones for antimalarial activity. , 2011, Experimental parasitology.

[11]  H. Balaram,et al.  Metabolic Fate of Fumarate, a Side Product of the Purine Salvage Pathway in the Intraerythrocytic Stages of Plasmodium falciparum* , 2011, The Journal of Biological Chemistry.

[12]  S. Dean,et al.  A Potential Interaction between Warfarin and Atovaquone , 2011, The Annals of pharmacotherapy.

[13]  F. Zsila,et al.  Combination of chiroptical, absorption and fluorescence spectroscopic methods reveals multiple, hydrophobicity-driven human serum albumin binding of the antimalarial atovaquone and related hydroxynaphthoquinone compounds. , 2010, Organic & biomolecular chemistry.

[14]  G. Biagini,et al.  Inhibiting Plasmodium cytochrome bc1: a complex issue. , 2010, Current opinion in chemical biology.

[15]  C. Guillemette,et al.  Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine , 2009, Drug Metabolism and Disposition.

[16]  Sozanne R. Solmaz,et al.  Structure of Complex III with Bound Cytochrome c in Reduced State and Definition of a Minimal Core Interface for Electron Transfer* , 2008, Journal of Biological Chemistry.

[17]  D. Lalloo,et al.  Preventing malaria in travellers , 2008, BMJ : British Medical Journal.

[18]  Andrew Owen,et al.  Acridinediones: Selective and Potent Inhibitors of the Malaria Parasite Mitochondrial bc1 Complex , 2008, Molecular Pharmacology.

[19]  D. Kramer,et al.  A drug-selected Plasmodium falciparum lacking the need for conventional electron transport. , 2008, Molecular and biochemical parasitology.

[20]  David Hinrichs,et al.  Antimalarial quinolones: synthesis, potency, and mechanistic studies. , 2008, Experimental parasitology.

[21]  J. Le bras,et al.  Plasmodium falciparum Malaria and Atovaquone-Proguanil Treatment Failure , 2008, Emerging infectious diseases.

[22]  P. Hunter,et al.  A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. , 2007, The Journal of antimicrobial chemotherapy.

[23]  S. Meshnick,et al.  Modeling the molecular basis of atovaquone resistance in parasites and pathogenic fungi. , 2007, Trends in parasitology.

[24]  I. Mcintosh,et al.  Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme , 2007, Drug Metabolism and Disposition.

[25]  Joanne M. Morrisey,et al.  Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum , 2007, Nature.

[26]  J. Lelièvre,et al.  Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[27]  J. Le bras,et al.  Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. , 2006, Microbes and infection.

[28]  G. Biagini,et al.  Functional Characterization and Target Validation of Alternative Complex I of Plasmodium falciparum Mitochondria , 2006, Antimicrobial Agents and Chemotherapy.

[29]  S. Owusu‐Ofori,et al.  Atovaquone-proguanil for treating uncomplicated malaria. , 2005, The Cochrane database of systematic reviews.

[30]  N. Suttorp,et al.  Malarone treatment failure not associated with previously described mutations in the cytochrome b gene , 2004, Malaria Journal.

[31]  K. Kain,et al.  Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  A. Baggish,et al.  Antiparasitic Agent Atovaquone , 2002, Antimicrobial Agents and Chemotherapy.

[33]  L. Trepanier,et al.  Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation , 2002, European Journal of Clinical Pharmacology.

[34]  M. Ashton,et al.  Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis , 2002, European Journal of Clinical Pharmacology.

[35]  G. Butcher,et al.  Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria , 2002, Malaria Journal.

[36]  D. Back,et al.  CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[37]  J. Montaner,et al.  Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients , 2001, AIDS.

[38]  Q. Cheng,et al.  Mutations in Plasmodium falciparumCytochrome b That Are Associated with Atovaquone Resistance Are Located at a Putative Drug-Binding Site , 2000, Antimicrobial Agents and Chemotherapy.

[39]  Christos Reppas,et al.  Forecasting the In Vivo Performance of Four Low Solubility Drugs from Their In Vitro Dissolution Data , 1999, Pharmaceutical Research.

[40]  T. Cheung.  Overdose of atovaquone in a patient with AIDS. , 1999, AIDS.

[41]  C. Gissi,et al.  Nucleotide Substitution Rate of Mammalian Mitochondrial Genomes , 1999, Journal of Molecular Evolution.

[42]  David R. Williams,et al.  Synthesis of Atovaquone. , 1999 .

[43]  K. K. Seymour,et al.  dCTP levels are maintained in Plasmodium falciparum subjected to pyrimidine deficiency or excess. , 1997, Annals of tropical medicine and parasitology.

[44]  N. White,et al.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo , 1997, Antimicrobial agents and chemotherapy.

[45]  P. Rolan,et al.  Disposition of atovaquone in humans , 1997, Antimicrobial agents and chemotherapy.

[46]  C. Canfield,et al.  Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum , 1997, Clinical pharmacology and therapeutics.

[47]  A. Vaidya,et al.  Atovaquone, a Broad Spectrum Antiparasitic Drug, Collapses Mitochondrial Membrane Potential in a Malarial Parasite* , 1997, The Journal of Biological Chemistry.

[48]  P. Rolan,et al.  Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. , 1996, British journal of clinical pharmacology.

[49]  P. Rolan,et al.  Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients , 1996, Antimicrobial agents and chemotherapy.

[50]  B. Sadler,et al.  Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine , 1996, Clinical pharmacology and therapeutics.

[51]  P. Chiodini,et al.  Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. , 1995, The Journal of antimicrobial chemotherapy.

[52]  J. Flaherty,et al.  ATOVAQUONE: A Review , 1993, The Annals of pharmacotherapy.

[53]  J. Falloon,et al.  Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. , 1993, The New England journal of medicine.

[54]  A. Hudson,et al.  Atovaquone - a novel broad-spectrum anti-infective drug. , 1993, Parasitology today.

[55]  M. Fry,et al.  Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). , 1992, Biochemical pharmacology.

[56]  R. Bevan,et al.  Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells. , 1991, Molecular pharmacology.

[57]  A. Hudson,et al.  In vitro activity of 2-cycloalkyl-3-hydroxy-1,4-naphthoquinones against Theileria, Eimeria and Plasmodia species , 1986 .

[58]  R. Williams,et al.  Novel anti-malarial hydroxynaphthoquinones with potent broad spectrum anti-protozoal activity , 1985, Parasitology.

[59]  G. Fawaz,et al.  The effect of lapinone (M-2350) on P. vivax infection in man. , 1951, The American journal of tropical medicine and hygiene.

[60]  L. Fieser,et al.  Naphthoquinone antimalarials; correlation of structure and activity against P. lophurae in ducks. , 1948, Journal of the American Chemical Society.

[61]  K. McKeage,et al.  Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria. , 2003, Drugs.

[62]  J. Hochman,et al.  Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. , 2000, The Journal of pharmacology and experimental therapeutics.

[63]  H. Webster,et al.  Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. , 1996, The American journal of tropical medicine and hygiene.

[64]  K. Goa,et al.  Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. , 1995, Drugs.

[65]  B. Weatherley,et al.  Examination of some factors responsible for a food-induced increase in absorption of atovaquone. , 1994, British journal of clinical pharmacology.

[66]  W. Gutteridge,et al.  566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. , 1991, Drugs under experimental and clinical research.

[67]  D. Hammond,et al.  Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. , 1985, Molecular and biochemical parasitology.

[68]  M. Mungthin,et al.  In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand , 2008, Malaria Journal.